Lee's Pharmaceutical Holdings Limited AI Stock Analysis
Want to see HK:0950 full AI Analyst Report?
Lee's Pharmaceutical Holdings Limited (0950) AI Stock Analysis
Lee's Pharmaceutical Holdings Limited
(HKEX:0950)
The overall score reflects solid but not top‑tier financial performance, with strong growth, healthy margins, conservative leverage and improving cash generation offset by negative TTM operating profit and historically uneven profitability. Attractive valuation, driven by a very low P/E and near‑4% dividend yield, meaningfully supports the score, while neutral‑to‑oversold technicals and relatively low volatility suggest limited downside but a lack of strong positive price momentum.
Lee's Pharmaceutical Holdings Limited (0950) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 630.05M
- Dividend Yield
- 5.50%
- Average Volume (3M)
- 553.72K
- Price to Earnings (P/E)
- 3.7
- Beta (1Y)
- 0.61
- Revenue Growth
- 7.05%
- EPS Growth
- 22.46%
- Country
- Hong Kong
- Employees
- 1,094
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as c...
How the Company Makes Money
The company primarily makes money by commercializing pharmaceutical products and related rights across its operating markets. Key revenue streams typically include: (1) Product sales: revenue from selling prescription medicines (including specialty/h...
Lee's Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Strong ~30% revenue growth, solid mid‑50% gross margins, rising net profit, low leverage, improving ROE and better operating/free cash flow support the score, but negative TTM operating profit, historically volatile margins and cash conversion, and only moderate returns on equity prevent a higher rating.
Income Statement
68PositiveBalance Sheet
78PositiveCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.94B | 1.44B | 1.40B | 1.05B | 1.23B | 1.27B |
| Gross Profit | 1.04B | 729.56M | 753.36M | 551.31M | 770.75M | 806.28M |
| EBITDA | 283.46M | 265.93M | 260.87M | 193.05M | 229.06M | 2.13B |
| Net Income | 167.27M | 91.94M | 93.10M | 16.70M | 51.28M | 1.99B |
Balance Sheet | ||||||
| Total Assets | 3.48B | 3.46B | 2.62B | 2.89B | 2.78B | 3.64B |
| Cash, Cash Equivalents and Short-Term Investments | 364.39M | 349.90M | 216.84M | 171.00M | 189.30M | 277.53M |
| Total Debt | 249.84M | 310.27M | 227.30M | 204.14M | 163.49M | 267.14M |
| Total Liabilities | 1.54B | 1.56B | 1.07B | 930.07M | 939.50M | 1.25B |
| Stockholders Equity | 2.13B | 2.05B | 1.65B | 2.04B | 1.92B | 2.46B |
Cash Flow | ||||||
| Free Cash Flow | 413.26M | 101.35M | 34.45M | -49.63M | 69.81M | -160.04M |
| Operating Cash Flow | 577.42M | 332.90M | 242.01M | 110.08M | 283.63M | 210.68M |
| Investing Cash Flow | -446.91M | -235.76M | -190.23M | -145.22M | -256.05M | -370.28M |
| Financing Cash Flow | -52.26M | 35.58M | -1.96M | 13.44M | -128.60M | 60.97M |
Lee's Pharmaceutical Holdings Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Negative. The current price of 1.05 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.12, and below the 200-day MA of 1.16, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.47 is Neutral, neither overbought nor oversold. The STOCH value of 50.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0950.
Lee's Pharmaceutical Holdings Limited Peers Comparison
Overall Rating
HK:023986Outperform- HK:095072.4Outperform
HK:263370Outperform
HK:089758.6Neutral
HK:149841Neutral
HK:165240Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 86Outperform | HKD 738.59M | 7.41 | 13.59% | 7.81% | 10.63% | 39.44% |
| HK:0950 | 72Outperform | HKD 641.83M | 3.71 | 8.02% | 5.50% | 7.05% | 22.46% |
| HK:2633 | 70Outperform | HKD 1.75B | 6.09 | 13.26% | 9.83% | -0.47% | -0.40% |
| HK:0897 | 59Neutral | HKD 412.32M | 97.22 | 0.34% | ― | -8.30% | -44.44% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1498 | 41Neutral | HKD 121.97M | -4.01 | -21.66% | ― | -6.71% | 43.14% |
| HK:1652 | 40Underperform | HKD 683.76M | -247.23 | -0.66% | ― | 18.14% | 98.32% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.05 | -0.69 | -39.62% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.35 | -0.11 | -23.91% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.17 | -43.00% | |
| HK:1652 | Fusen Pharmaceutical Co., Ltd. | 0.93 | 0.11 | 13.41% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.37 | 0.11 | 5.05% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.92 | -0.45 | -32.75% |
Lee's Pharmaceutical Holdings Limited Corporate Events
Lee’s Pharm licenses next-generation PARP1 cancer drug OC-3 for Greater China and Southeast Asia
Lee’s Pharmaceutical has strengthened its oncology portfolio by securing exclusive rights from U.S. biotech 1cBio to develop, manufacture and commercialise OC-3, a next-generation PARP1-selective inhibitor, across Mainland China, Hong Kong, Macau, Ta...
Lee’s Pharmaceutical Delivers Strong Interim Profit Growth on Higher-Margin Drug Mix
Lee’s Pharmaceutical reported a solid set of interim results for the six months ended 30 June 2026, with revenue rising 14.6% year-on-year to HK$796.6 million and profit attributable to shareholders surging 41.4% to HK$95.0 million. Earnings per shar...
Lee’s Pharmaceutical Declares Interim Cash Dividend for First Half of 2026
Lee’s Pharmaceutical Holdings Limited has declared an interim ordinary cash dividend of HKD 0.035 per share for the six months ended 30 June 2026, covering the financial year ending 31 December 2026. The move underscores the company’s commitment to r...
Lee’s Pharmaceutical forecasts higher interim profit on stronger margins and product mix
Lee’s Pharmaceutical Holdings Limited expects to report an unaudited net profit attributable to shareholders of HK$85 million to HK$95 million for the six months ended 30 June 2026, up from HK$67.2 million a year earlier. The interim results are slat...
Lee’s Pharmaceutical Sets Board Meeting to Review 2026 Interim Results and Dividend
Lee’s Pharmaceutical Holdings Limited has scheduled a board meeting for 31 August 2026 in Hong Kong to review and approve the group’s unaudited interim results for the six months ended 30 June 2026. The board will also consider whether to recommend a...
Lee’s Pharm Wins NMPA Nod to Trial First In-House ADC ZK2401
Lee’s Pharmaceutical has secured acceptance from China’s National Medical Products Administration for an Investigational New Drug application for ZK2401, a proprietary antibody-drug conjugate built on its approved anti-PD-L1 antibody Socazolimab and...
Lee’s Pharm Licenses Interferon Alpha-2b to Ashlins for Markets Outside Greater China
Lee’s Pharmaceutical Holdings Limited has signed an exclusive license-out and supply agreement with Ashlins Ocular Pharmaceuticals, a U.S.-based biopharmaceutical company, for Interferon Alpha-2b products in all markets outside Mainland China, Hong K...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 17, 2026